Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
-
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
-
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
-
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
-
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
-
PharmAla provides corporate update following AGM
-
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
-
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
-
PharmAla signs all-cash agreement to consult for Red Light Holland
-
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines